Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)

Shanghai Public Health Clinical Center0 sitesStarted: TBDLast updated: February 20, 2023

Conditions

Trial Snapshot

No summary available.

•(1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium;
•(2) Those who have been diagnosed with TCM as epidemic-closed lungs;
•(3) Inpatients aged 18 to 75 years, regardless of gender;
•(4) Voluntarily receive treatment with the drug and sign informed consent. The informed consent process complies with relevant GCP regulations.

•(1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;
•(2) Preparing pregnant, pregnant and lactating women;
•(3) Patients with allergies (referring to allergies to two or more medicines, foods or known ingredients in this study);
•(4) Patients with mental illness, or have no cognitive ability;
•(5) Patients with an estimated survival time of less than 48 hours from the start of screening;
•(6) Those who have been intubated or mechanically ventilated at the time of screening;
•(7) Obvious symptoms of heart, liver, kidney or various other systems, ALT, AST exceed 1.5 times the upper limit of normal value;
•(8) Believed to be not suitable to participate in clinical trials by investigator.

Sponsor